Biosciences firms' take on the recession: Not as bad as everyone else

From our recent conversation with 5AM Ventures Managing Partner Andy Schwab to press releases from DSM and Bayer, investors and developers at the forefront of biosciences feel set to take the current economic turmoil in stride, at least compared to other industries. Andy echoed sentiments heard thro...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Pear Therapeutics CEO claims Novartis trial of schizophrenia therapeutic was flawed; tensions grow between digital therapeutics and pharma

News Commentary | April 16, 2021

The CEO of Pear Therapeutics is claiming that trial irregularities are causing misleading results regarding the schizophrenia product rolled out last year. While the results of this study are unlikely to change anything for Pear Therapeutics directly, the claimed lack of rigor in the trial speaks to... Not part of subscription

Scientists discover which human genes help fight COVID-19 infection

News Commentary | April 19, 2021

Despite the speed of vaccine development, we know little about how the human body responds to COVID‑19. Some light is now being shed on this puzzle. We know that the body releases interferons (think first responders during an accident), a set of signaling proteins, upon COVID‑19 infection. The study... Not part of subscription

Google-backed Calico and AbbVie announce second extension of a long-standing partnership to tackle aging-related diseases

News Commentary | July 30, 2021

Google‑backed Calico and pharma giant AbbVie are doubling down on tackling aging‑related diseases with this second partnership extension. Twenty early‑stage programs have been developed across oncology and neurodegeneration, with the lead oncology target, which acts at multiple steps in the cancer ... Not part of subscription